journal
https://read.qxmd.com/read/37650775/contact-lens-disinfectants-against-acanthamoeba-keratitis-an-overview-of-recent-patents-and-future-needs
#21
EDITORIAL
Ruqaiyyah Siddiqui, Naveed A Khan
No abstract text is available yet for this article.
August 31, 2023: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/37477491/patent-highlights-october-november-2022
#22
JOURNAL ARTICLE
Hermann Am Mucke
A snapshot of recent noteworthy developments in the patent literature of relevance to pharmaceutical and medical research and development.
July 21, 2023: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/37477487/patent-analysis-of-novel-therapeutic-approaches-for-treating-alzheimer-s-disease-2018-2023
#23
EDITORIAL
Faiza Saleem, Fouzia Naz, Khalid M Khan
No abstract text is available yet for this article.
July 21, 2023: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/37184587/review-of-epo%C3%A2-board-of-appeal-antibody-decisions-in-2022
#24
EDITORIAL
Daniel Hilton, Vicki Allen, Graham Lewis
No abstract text is available yet for this article.
May 15, 2023: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/37140357/riluzole-and-its-prodrugs-for-the-treatment-of-alzheimer-s%C3%A2-disease
#25
JOURNAL ARTICLE
Rami A Al-Horani
Current medications for Alzheimer's disease help manage symptoms and behavioral problems. Nevertheless, they do not slow the progression of cognitive decline or dementia. A potential approach for treating Alzheimer's disease is to target neurons that are sensitive to disease pathobiology such as glutamatergic neurons. Several patents disclosed methods for treating Alzheimer's disease by administering riluzole or its prodrugs. Clinical trials revealed that 6 months treatment using riluzole or troriluzole is associated with a slower decline in the tomographic measures of the positron emissions of cerebral glucose metabolism in Alzheimer's patients...
May 4, 2023: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/37140356/patents-pharmaceutical-industry-and-healthcare
#26
EDITORIAL
Ruqaiyyah Siddiqui, Naveed A Khan
No abstract text is available yet for this article.
May 4, 2023: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/37078761/patent-landscape-highlighting-double-edged-scaffold-of-a-wnt5a-agonizing-peptide-foxy5
#27
JOURNAL ARTICLE
Vikas Yadav, Rubina Islam, Hardeep Singh Tuli
Aberrant expression of the WNT signaling pathway has been associated with cancer progression and recurrence. Research over the decades has led to development of WNT-targetable small molecules, but has faced challenges in translating to clinics. Unlike WNT/β-catenin inhibitors, WNT5A-mimicking peptide, Foxy5 has shown encouraging efficacy in impairing metastasis of cancers with low or absent WNT5A expression. Recent patent application US20210008149 advocates the implication of Foxy5 for treatment and prevention of cancer relapse...
April 20, 2023: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/37013831/patent-highlights-august-september-2022
#28
JOURNAL ARTICLE
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
April 4, 2023: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/36802922/compulsory-licensing-of-patents
#29
REVIEW
Narayanasamy Kumutha, Narayanasamy Amutha, Govindasamy S Venkatesh
Compulsory licensing (CL) is a mechanism made by the government to provide balance between the monopoly right holders and the third person with public interest by ensuring the ease availability of the patented products at reasonable rate. This paper discusses the background criteria for getting CL in India as per the Indian Patent Act, 1970 starting from the concepts outlined in the Trade-Related Aspects of Intellectual Property Rights agreement. We reviewed the case studies for the accepted and rejected CL in India...
February 21, 2023: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/36722324/-patenting-trends-in-the-pharmaceutical-field-of-mexican-universities
#30
JOURNAL ARTICLE
Gabriela Sanchez-Esgua, Juan Reyes-Alvarez, Martin Perez-Santos
Aim : pharmaceutical patenting activity in developing countries, including Mexico, is unknown. Objective : determine the activity of pharmaceutical patents by Mexican universities. Method : using 'university' as keyword and A61K, A61P and C07 as International Patent Classification codes, was searched to generate a perspective of pharmaceutical patent applications by Mexican universities. Results : 227 patents (186 granted patents + 41 not-granted patents) were claimed in the period 2000-2018. The leading university was the National Autonomous University of Mexico, followed by the Instituto Politecnico Nacional, Universidad Autonoma de Nuevo León, and Universidad Autonoma de Puebla...
February 1, 2023: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/36722320/photoresponsive-liposomes-an-alternative-of-elisa-for-the-detection-of-low-quantities-of-target-substances
#31
JOURNAL ARTICLE
Ramesh Joga, Hitesh Kumar Behera, Chetan Dushant Sabanis, Simran, Sandeep Kumar, Neeraj Kumar
Photoresponsive liposome development is needed to serve as a facile alternative to ELISA which is ineffective for detecting small levels of biomarkers due to low detection sensitivity. The US20210396744 patent application outlines novel photoresponsive liposomes for the detection of target substances with the aid of light. Although versatile, there may be possible stability issues that can be avoided with the appropriate selection of liposome components. Furthermore, the clinical success of this technology depends on many parameters like plasma stability, efficient loading of photosensitive components in the membrane, and immobilization of molecular recognition elements to the membrane...
February 1, 2023: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/36511100/therapeutic-potential-of-pogostemon-cablin-%C3%A2-herb-a-comprehensive-review
#32
REVIEW
Archana Thakur
Pogostemon cablin ( Pogostemon patchouli or Patchouli) is known for its essential oil and is a popular medicinal herb in Indian Ayurveda and traditional Chinese medicine. This review covers patent articles on the P. cablin plant's therapeutic effects. The patent literature was collected using a thorough, comprehensive search on databases like Thomson Innovation, Espacenet, Patentscope, The Lens and Patent digital libraries of different Jurisdictions, including IPO, USPTO, CNIPA, inPASS, KIPO, JPO, etc. Despite the vast number of review articles on non-patent literature, none of the articles reviewed the patent literature...
December 13, 2022: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/36511078/patent-highlights-june-july-2022
#33
JOURNAL ARTICLE
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
December 13, 2022: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/36475455/recent-developments-in-silver-nanoparticles-utilized-for-cancer-treatment-and-diagnosis-a-patent-review
#34
JOURNAL ARTICLE
Shripad M Patil, Runjhun Tandon, Nitin Tandon
Nanotheranostics is a young but rapidly expanding science that incorporates elements of therapy and diagnostics in a unique and miniscule area of research. The potential to combine diagnostic and therapeutic abilities inside a complete unit opens up interesting possibilities for innovative biomedical research. Silver-based nanoparticles, for instance, are widely utilized as pharmacological and biomedical imaging molecules, and hence offer a lot of potential for the development of versatile targeted therapy compositions...
December 7, 2022: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/36420707/patent-developments-via-schiff-bases-in-medicinal-chemistry
#35
EDITORIAL
Maham Haider, Khalid Mohammed Khan
No abstract text is available yet for this article.
November 24, 2022: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/36382542/co-processed-tablet-excipient-composition-its-preparation-and-use-us10071059-b2-patent-spotlight
#36
JOURNAL ARTICLE
Sajal Jain, Ritu Rathi, Upendra Nagaich, Inderbir Singh
Co-processing involves the incorporation of one excipients into the particle structure of other excipients to overcome the deficiencies of each excipients. The current patent describes the co-processing of microcrystalline cellulose and mannitol via fluid bed agglomeration with an aim to limit the use of lubricant in tablet composition. The co-processed excipients blend was compared with the physical blend of excipients and characterized for scanning electron microscopy, disintegration and hardness. The average particle size of co-processed excipients was less than 0...
November 16, 2022: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/36366974/pyrrolidine-derivatives-as-antibacterial-agents-current-status-and-future-prospects-a-patent-review
#37
JOURNAL ARTICLE
Aeyaz A Bhat, Nitin Tandon, Runjhun Tandon
Bacterial infections are increasingly epitomizing major global health concerns, with rising death rates. Since the most complete assessment of the worldwide impact of antimicrobial resistance to date, with over 1.2 million people dead in 2019 as a direct result of antibiotic-resistant bacterial infections. The majority of antimicrobial drugs have been associated with a multitude of adverse effects including financial costs as well. Pyrrolidine derivatives have sparked the interest of researchers to create novel synthetic molecules with minimal side effect and drawbacks...
November 11, 2022: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/36354044/oral-insulin-delivery-a-patent-review
#38
JOURNAL ARTICLE
Shivani Sharma, Amit Mittal, Anuradha Mehra
Insulin, on oral administration, is very troublesome because of its limited bioavailability. The evolution of oral insulin delivery formulations is greatly desired for non-invasive therapy by overcoming its low bioavailability, GIT enzymatic deactivation, poor lipophilicity and low stability. Different approaches have been proposed to boost oral insulin bioavailability in insulin-delivery systems and emerging effective therapies by using nanoparticle formulation, nanocapsid, modified chitosan particles, polydopamine microcapsules, and nanoliposomes...
November 10, 2022: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/36354042/4-imidazo-1-2-a-pyridin-3-yl-pyrimidine-derivatives-as-anticancer-agents
#39
JOURNAL ARTICLE
Rami A Al-Horani
A series of 4-(imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives are claimed as inhibitors of c-KIT and as potential treatments for cancer. Their chemical preparation and biological evaluation against imatinib-resistant tumor cells have been described. Several claimed molecules have excellent IC50 values in the nanomolar range. Several molecules were also selective against a wide panel of kinases. Few specific inhibitors have been found to have promising oral bioavailability and acceptable to excellent values regarding the inhibition of hERG channel...
November 10, 2022: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/36943009/papers-from-the-first-international-conference-on-innovation-and-intellectual-property-rights
#40
JOURNAL ARTICLE
Michael Bell, Runjhun Tandon
No abstract text is available yet for this article.
November 2022: Pharmaceutical Patent Analyst
journal
journal
47821
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.